Silence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director.
Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in over 30 years experience in the biopharmaceutical industry, with special expertise in strategic partnerships with Big Pharma. The Board member of the British Industry Organisation (BIA) is currently a non-executive director for cancer immunotherapy specialist Targovax ASA which recently announced new patents for its colon cancer RAS-targeting candidate drug TG02. Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV.
Forbion, a European life science venture capital firm, today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.
Cell Medica, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Companys Board of Directors.
Tigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.
Josh Muntner has been appointed Chief Financial Officer of Mesoblast. He will be based in New York.
PureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
Hikma Pharmaceuticals PLC announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer.
Sygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the companys international growth plans.